Alzheimer’s disease research has spent decades fixated on amyloid plaques and tau tangles, but a team of scientists in China has turned its attention to a different suspect: the brain’s own immune cells, and the way they burn fuel. In a study published in Materials Today Bio, researchers report that nanoparticles engineered from a polysaccharide extracted from Panax notoginseng, the herb better known as notoginseng or sanqi, can ferry two plant-derived drug candidates across the blood-brain barrier, home in on overactivated microglia, and rewire their metabolism. In APP/PS1 mice, a widely used model of Alzheimer’s disease, the treatment improved spatial memory and daily behavior, reduced amyloid burden, and restored the energy-producing machinery of brain tissue. The work belongs to a growing movement in neurodegeneration research that treats microglia not merely as inflammatory bystanders but as dynamic regulators of protein clearance, synaptic remodeling, and tissue repair, whose malfunction can potentially be corrected.
The scientific logic rests on a phenomenon called immunometabolic reprogramming. Microglia, the resident innate immune cells of the central nervous system, normally run on mitochondrial oxidative phosphorylation, an efficient mode of energy generation that sustains their quiet surveillance of the brain. Confronted with amyloid-β aggregates, oxidative stress, and persistent inflammatory signals, however, they shift toward aerobic glycolysis, the rapid but wasteful glucose-burning program familiar from cancer cells and acutely activated immune cells. Useful for a short burst of defense, this metabolic posture becomes destructive when it hardens into a permanent state, locking microglia into a pro-inflammatory phenotype characterized by excessive reactive oxygen species, crippled respiration, and amplified cytokine output. At the center of the malfunction sits a three-part signaling circuit. AMPK acts as the cell’s fuel gauge, preserving mitochondrial homeostasis and restraining inflammation. mTOR integrates nutrient and growth signals to drive anabolic, glycolytic metabolism, while HIF-1α, which mTOR activates, switches on the transcription of glycolytic enzymes and glucose transporters. In the Alzheimer’s brain, AMPK activity falters even as mTOR and HIF-1α remain stubbornly switched on, and the resulting inflammation-metabolism loop feeds on itself.
Rather than blocking a single inflammatory molecule, the team drew on the traditional Chinese medicine principle of “BuShen HuoXue,” tonifying the kidney and activating blood circulation, long applied to disorders of cognitive decline. From that framework they selected two compounds: icaritin, a flavonoid from Epimedium reported to support energy sensing and mitochondrial health, and tanshinone IIA, a diterpene from Salvia miltiorrhiza with documented anti-neuroinflammatory activity. Network pharmacology suggested the pair converges on AMPK and mTOR signaling, but both molecules are handicapped as drugs: they dissolve poorly in water, cross the blood-brain barrier inefficiently, and never reach meaningful concentrations inside diseased microglia. The researchers’ answer, developed by Ge Zhang, Ying Yang, Xue-tao Li, Yang Yu, and colleagues, was to encapsulate them within nanoparticles built from Panax notoginseng polysaccharide, a biocompatible, biodegradable macromolecule with intrinsic antioxidant and immunomodulatory activity that the team treated not as an inert wrapper but as a functional component of the therapy itself.
The resulting platform, named KPBIT@NPs, is a small feat of materials chemistry. The researchers first grafted 4-carboxyphenylboronic acid pinacol ester, or CPBA, onto the polysaccharide, adding hydrophobic domains that let the polymer chains self-assemble into spherical particles in water. They then attached KLVFFAED, a peptide taken from the amyloid-β sequence itself, exploiting its ability to engage RAGE, the receptor for advanced glycation end products, which is upregulated in Alzheimer’s disease and participates in amyloid transport across the blood-brain barrier. Proton nuclear magnetic resonance and Fourier transform infrared spectroscopy confirmed each modification step, and systematic variation of the CPBA feed ratio revealed a non-linear relationship between grafting density and assembly behavior, with a grafting degree of 8.95 percent giving the lowest critical aggregation concentration while preserving water solubility. The final formulation formed uniform, near-spherical particles about 79 nanometers in diameter with a near-neutral surface charge, encapsulating 92 percent of the icaritin and 87 percent of the tanshinone IIA and remaining stable in serum for two weeks.
The most elegant feature is the particles’ responsiveness to the disease environment. The phenylboronic ester bonds anchoring CPBA to the polysaccharide are cleaved by reactive oxygen species, which accumulate in the inflamed Alzheimer’s brain. When the nanoparticles were exposed to hydrogen peroxide in the laboratory, transmission electron microscopy showed them fragmenting, and drug release accelerated in a concentration-dependent manner from mild oxidative stimulation to high oxidative challenge; in neutral buffer, the cargo stayed locked inside. To test delivery, the team built a blood-brain barrier model with bEnd.3 endothelial cells cultured in Transwell chambers above BV2 microglia, then degraded the barrier with amyloid-β and lipopolysaccharide to mimic disease conditions while preserving measurable barrier integrity, verified by transendothelial electrical resistance, sodium fluorescein permeability, and tight-junction staining. KLV-modified nanoparticles crossed the injured barrier far more efficiently than unmodified versions and were taken up more avidly by the microglia below, an advantage that collapsed when cells were pretreated with the RAGE inhibitor FPS-ZM1. In living animals, near-infrared imaging showed the modified particles circulating for up to 72 hours and accumulating in APP/PS1 mouse brain well above non-targeted controls.
Inside microglia, the two drugs proved better together than apart. Using the SynergyFinder platform, the team screened combinations of free icaritin and tanshinone IIA in BV2 microglia injured by amyloid-β and lipopolysaccharide and identified a 1:1 molar ratio as optimal, with synergy scores above the threshold for significant cooperation. Nanoparticles loaded at that ratio outperformed single-drug and non-targeted formulations across every assay. They cut intracellular reactive oxygen species, lowered malondialdehyde, a marker of lipid peroxidation, and raised glutathione and catalase. They suppressed interleukin-6, interleukin-1β, and tumor necrosis factor-α while boosting the reparative markers arginase-1 and interleukin-10. Flow cytometry and immunofluorescence tracked a phenotypic migration from the pro-inflammatory M1 state, marked by CD86, toward the restorative M2 state, marked by CD206, and JC-1 staining showed damaged mitochondrial membrane potential substantially restored. Conditioned medium from treated microglia, transferred onto HT22 neurons, reduced neuronal apoptosis and oxidative stress, demonstrating that reprogrammed microglia become actively protective toward their neighbors.
The mechanism was then interrogated at the level of signaling proteins. Western blotting revealed that stressed microglia carried a depressed p-AMPK/AMPK ratio alongside elevated p-mTOR/mTOR and HIF-1α, the biochemical signature of a cell stuck in glycolytic overdrive, and KPBIT@NPs reversed all three markers. Downstream metabolic enzymes told the same story: expression of PFKFB3, a rate-limiting glycolytic regulator, fell, while inhibitory phosphorylation of PDHE1α declined, freeing pyruvate to enter the tricarboxylic acid cycle. Real-time flux analysis measured a drop in the extracellular acidification rate, a proxy for glycolysis, and a rise in the oxygen consumption rate, the direct readout of mitochondrial respiration, with basal respiration, ATP production, maximal respiration, and spare respiratory capacity all climbing. The glycolytic enzyme LDHA dimmed while ATP5A, a core subunit of mitochondrial ATP synthase, brightened. Crucially, the AMPK inhibitor Compound C blunted these effects and the mTOR activator MHY1485 reversed them, establishing that the AMPK-mTOR/HIF-1α axis is not merely correlated with the therapeutic effect but required for it.
Computational analyses reinforced the drug pairing. The team assembled a network spanning 48 active compounds from Epimedium and Salvia miltiorrhiza, 736 predicted drug targets, and 16,820 Alzheimer’s-related genes, converging on 688 shared targets. Pathway enrichment placed AMPK and mTOR signaling among the most significantly represented routes, with HIF-1α emerging as a hub node, and molecular docking with AutoDock Vina returned favorable binding energies for both compounds against both proteins: tanshinone IIA bound AMPK at −9.70 kilocalories per mole and mTOR at −8.83, while icaritin registered −8.17 and −7.17 respectively, with hydrogen bonding and hydrophobic contacts stabilizing the interactions. The computations suggest that this classical herb pair achieves, through complementary chemistry, precisely the dual regulation that Alzheimer’s pathology disrupts.
In APP/PS1 mice, the cellular effects translated into behavior and brain structure. Treated animals located the hidden platform faster in the Morris water maze, spent more time in the target quadrant, crossed the platform location more often, and built more coherent nests, a standard measure of daily function. Amyloid plaque burden in cortex and hippocampus shrank, Nissl staining revealed healthier neuronal layers, NeuN staining indicated greater neuronal survival, and Golgi staining showed dendritic trees with restored length and branching. Transmission electron microscopy of hippocampal tissue found mitochondria with intact cristae and membranes where model mice carried swollen, disrupted organelles. Whole-brain biochemical assays completed the picture: activities of the tricarboxylic acid cycle enzymes isocitrate dehydrogenase, α-ketoglutarate dehydrogenase, and succinate dehydrogenase, along with respiratory chain complexes I through V and total ATP content, all rebounded, while lactate, pyruvate, hexokinase, and lactate dehydrogenase, the fingerprints of glycolytic accumulation, receded. Markers of astrocyte and microglial activation, GFAP and IBA-1, fell, and co-staining confirmed the CD86-to-CD206 phenotypic flip within IBA-1-positive microglia in the brain itself.
Safety data were reassuring at this stage: hemolysis rates stayed below accepted thresholds, organ histology appeared normal, blood counts were unremarkable, and serum cytokines showed no peripheral inflammatory activation. The authors are candid about limitations. Their brain metabolic measurements relied on bulk homogenates that cannot separate microglial metabolism from that of neurons or astrocytes, direct intracerebral colocalization of the nanoparticles was not obtained, and long-term biodistribution, biodegradation, and clearance remain unexamined. They propose a three-stage follow-up combining single-cell multi-omics with spatial metabolic imaging, extracellular flux and isotope-tracing assays on purified primary microglia, and microglia-specific blockade of the AMPK-mTOR/HIF-1α axis to establish cell-autonomous causality. Even with those caveats, the study delivers a proof of concept with wider implications: a natural polysaccharide can be engineered into a carrier that is not passive cargo space but an active participant in therapy, delivering two synergistic plant compounds to the exact immune cells whose metabolic derailment helps drive neurodegeneration. If the framework survives more advanced preclinical testing, it could extend beyond Alzheimer’s disease to other disorders, from Parkinson’s disease to stroke, in which inflammation and metabolism fail together.
Subject of Research: Microglia-targeted polysaccharide nanoparticles that reprogram immunometabolism via the AMPK-mTOR/HIF-1α axis to alleviate Alzheimer’s disease
Subject of Research: Technology and Engineering
Article Title: Microglia-targeted Panax notoginseng polysaccharide nanoparticles alleviate Alzheimer’s disease via AMPK-mTOR/HIF-1α-mediated immunometabolic reprogramming
Article References: Zhang, G., Kong, L., Guo, R.-B., Ding, S.-W., Liu, Y., Zang, J., Zheng, Y., Wei, B., Chen, Z.-C., Yang, Y., Li, X.-T., & Yu, Y. (2026). Microglia-targeted Panax notoginseng polysaccharide nanoparticles alleviate Alzheimer’s disease via AMPK-mTOR/HIF-1α-mediated immunometabolic reprogramming. Materials Today Bio, 40, Article 103620. https://doi.org/10.1016/j.mtbio.2026.103620
Image Credits: AI Generated
DOI: 10.1016/j.mtbio.2026.103620
Keywords: Alzheimer’s disease, microglia, immunometabolic reprogramming, AMPK-mTOR/HIF-1α signaling, Panax notoginseng polysaccharide, icaritin, tanshinone IIA, blood-brain barrier, ROS-responsive nanoparticles, neuroinflammation, APP/PS1 mice, nanomedicine
Cite Scienmag News
APA
MLA
Chicago
Cassandra Pierce. (August 30, 2026). Notoginseng polysaccharide nanoparticles reprogram microglia metabolism to ease Alzheimer’s disease. Scienmag. https://scienmag.com/notoginseng-polysaccharide-nanoparticles-reprogram-microglia-metabolism-to-ease-alzheimers-disease/
Cassandra Pierce. “Notoginseng polysaccharide nanoparticles reprogram microglia metabolism to ease Alzheimer’s disease.” Scienmag, 30 August 2026, https://scienmag.com/notoginseng-polysaccharide-nanoparticles-reprogram-microglia-metabolism-to-ease-alzheimers-disease/. Accessed 30 August 2026.
Cassandra Pierce. “Notoginseng polysaccharide nanoparticles reprogram microglia metabolism to ease Alzheimer’s disease.” Scienmag. August 30, 2026. https://scienmag.com/notoginseng-polysaccharide-nanoparticles-reprogram-microglia-metabolism-to-ease-alzheimers-disease/
Copy citation
Download RIS
Tags: Alzheimer’s diseaseAlzheimer’s mouse modelsamyloid plaque clearanceblood-brain barrier drug deliverymicroglia energy regulationmicroglia immunometabolic reprogrammingmicroglia metabolismmicroglia role in amyloid clearancemicroglia-targeted therapiesmitochondrial energy restoration in brainnanomedicine for neurodegenerative diseasesneurodegeneration therapyneuroinflammationneuroinflammation modulationnotoginseng extract in neurodegenerationPanax notoginsengplant-derived therapeuticsplant-derived therapeutics for Alzheimer’spolysaccharide nanoparticles
